Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio (NASDAQ: BLTE) reported additional positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1, presented at the ASRS 2026 Annual Meeting. Tinlarebant is described as the first therapeutic candidate to demonstrate clinical efficacy in this indication, having met the primary endpoint.
According to Belite Bio, quantitative autofluorescence, a marker of toxic bisretinoid accumulation, remained stable to slightly decreased (around 2%) at month 25 in tinlarebant-treated subjects, versus an approximately 20% increase with placebo. The 104‑patient, 2:1 randomized trial previously showed a statistically significant 35.7% reduction in retinal lesion growth versus placebo, with tinlarebant reported as well tolerated. The company also completed a New Drug Application for tinlarebant to the U.S. FDA.
Belite Bio (NASDAQ: BLTE) will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET. A live webcast and 90-day replay will be available via the company’s investor relations website.
Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on July 9, 2026 at 12:30 pm ET.
The live webcast and 90-day replay will be available under “Events” in the investor relations section of the Belite Bio website.
Belite Bio (NASDAQ: BLTE) announced oral presentations of Phase 3 DRAGON trial data for tinlarebant in Stargardt disease at two medical meetings.
Data will be shared at the ISCEV 2026 Symposium in Sydney and the ASRS 2026 Annual Meeting in Montréal in July 2026.
Belite Bio (NASDAQ:BLTE) has completed its rolling New Drug Application submission to the U.S. FDA for tinlarebant, a once-daily oral therapy for Stargardt disease type 1 (STGD1). The NDA, submitted under Breakthrough Therapy Designation, now enters a 60-day FDA filing review period.
According to the company, Phase 3 DRAGON trial results showed tinlarebant significantly reduced the growth rate of retinal lesions versus placebo, supporting its potential as the first approved treatment for STGD1, a rare inherited retinal disease with no current FDA-approved therapies.
Belite Bio (NASDAQ: BLTE), a clinical-stage drug developer targeting degenerative retinal diseases with significant unmet medical needs, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 pm ET.
The presentation webcast and 90-day replay will be available in the Events section of Belite Bio’s investor relations website.
Belite Bio (NASDAQ: BLTE) reported unaudited Q1 2026 results and key clinical milestones. The company initiated a rolling NDA submission to the FDA for tinlarebant in STGD1, targeting completion in Q2 2026, and completed hiring of key commercial leadership as commercialization preparation advances.
Phase 3 DRAGON in adolescent STGD1 is completed, while DRAGON II and pivotal GA PHOENIX trials have finished enrollment. As of March 31, 2026, Belite Bio held $276.4M in cash and $522.2M in U.S. treasuries, and recorded a GAAP net loss of $26.9M.
Belite Bio (NASDAQ: BLTE) received orphan drug status from Swissmedic for tinlarebant in Stargardt disease (STGD1). Tinlarebant met the primary endpoint in the global Phase 3 DRAGON trial, showing a 35.7% reduction in retinal lesion growth versus placebo. A rolling NDA submission to the FDA is underway, with completion expected in 2Q 2026. Tinlarebant also holds Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in major markets.
Belite Bio (NASDAQ: BLTE) will deliver an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) in Nanjing on May 22, 2026.
The talk will highlight previously disclosed Phase 3 DRAGON trial topline results for tinlarebant in adolescent Stargardt disease type 1, including a 35.7% reduction in atrophic retinal lesion growth versus placebo and a generally well tolerated safety profile.
Belite Bio (NASDAQ: BLTE) will host a webcast on May 20, 2026 at 4:30 p.m. ET to discuss first quarter 2026 financial results and provide a business update. Investors can access the live webcast and a 90-day replay via the company’s investor relations website.